Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2991+1655 A>G CEP290 mRNA.

Abstract: The present invention provides aphenothiazine derivative for use in preventing and/or treating infectious purpura or purpura fulminans, wherein infection is caused by a bacterium. The present invention further relates to a composition for the use in preventing and/or treating infectious purpura or purpura fulminans comprising a phenothiazine derivative and an antibiotic selected in the group consisting of beta-lactams, aminoglycosides or dexamethasone.

Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydro-carbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.

Abstract: The invention relates to a method for automatically processing at least one image slice of a given part of at least one lung of a patient suffering from a pathology that causes a bronchial infection by diffuse dilatation of the bronchial tubes of the lungs, the method comprising steps of segmenting (102) the at least one image slice of the given part of the lung, in order to produce a histogram characterising the pulmonary density of the given part of the lunch, by means of the voxels of the at least one image slice, each voxel being assocaited with a given pulmonary density; calculating (104) a threshold, from the histogram, corresponding to a threshold pulmonary density, based on at least one characteristic of the histogram, a first characteristic being the mode of the histogram; determining (106) from the at least one image slice of the given part of the lung, a pulmonary volume having a pulmonnar density higher or lower than the calculatedd threshold, corresponding to the sum of the voxels having a pulmon

Abstract: The present invention relates to a method for treating MI or AMI in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of an agent capable of depleting CD8 T cells. More particularly, this present invention relates to a method for treating acute myocardial infarction by reducing the size of necrosis and limiting 10 the post ischemic left ventricular remodeling.

Abstract: The invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, to a supramolecular polymer formed of capped cyclodextrin-hydrophobic moiety conjugates according to the invention and to a siRNA-cyclodextrin complex comprising a supramolecular polymer according to the invention. The invention also relates to a method for manufacturing the capped cyclodextrin-hydrophobic moiety conjugate, the supramolecular polymer, the siRNA-cyclodextrin complex according to the invention. The capped cyclodextrin-hydrophobic moiety conjugate of the invention comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker to one of the carbon atoms of the cap. The invention can be used for various applications in particular in the pharmaceutical field.

Abstract: The invention relates to a process for determining an infiltration profile of biological cells of interest in a biological object of interest from a digital histopathological image of biological tissues, a histological stain having previously been applied to the biological tissues, comprising generating a biological cell detection image, pixels associated with the histological stain on the histopathological image being of a predetermined color on said image, determining a distance map comprising distance iso-curves to the boundary of the biological object, and, from the distance map, calculating a curve representative of the surface density of biological cells of interest as a function of distance to the boundary, by counting, for each boundary distance value, pixels that are both of the predetermined color on the detection image and located between the iso-curve associated with said distance value and the consecutive iso-curve.

Abstract: The present invention relates to a new method for quantifying key components of manual dexterity. The present invention also provides methods for diagnosing impaired upper limb and/or hand function in patients based on how these components are affected.

Abstract: The present invention relates to methods and pharmaceutical compositions of inducing immune tolerance by mucosal vaccination with Fc-coupled antigens. In particular, the present invention relates to a method for inducing tolerance to one antigen of interest in a subject in need thereof, comprising the mucosal administration to the subject of a therapeutically effective amount of a recombinant chimeric construct comprising a FcRn targeting moiety and an antigen-containing moiety.

Abstract: The present invention relates to the field of muscle regeneration, and more particularly to the replenishment of the in vivo muscle stem cells pool. It more specifically relates to a 5-hydroxytryptamine B1 receptor-stimulating agent, and to a composition comprising said agent, for use as i) a promoter of satellite cells self-renewal and/or differentiation, and/or ii) an agent preventing and/or inhibiting the satellite cells pool exhaustion. The invention further encompasses therapeutic and screening methods.

Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.

Abstract: The present invention relates to an in vitro method of culturing a segmented filamentous bacterium strain, comprising co-culturing said segmented filamentous bacterium strain with a eukaryotic host cell, wherein the culture is performed at an O2 level inferior to 5% in a rich tissue culture liquid medium containing bacterial medium components including iron. The present invention also relates to methods for genetically modifying a segmented filamentous bacterium strain comprising a step a culturing the strain in vitro.

Abstract: The present invention relates to a composition comprising at least one poloxamer compound for use in the treatment of a fistula in an individual.

Abstract: The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.

Abstract: An optical system for shaping a wavefront of an electric field of an input light beam to be projected into a target volume including a first optical element, a spatial light modulator used to control light distribution in at least one transverse plane in the target volume. An intermediate optical element located on an optical axis, after the first optical element on a trajectory of the light beam for modulating the phase or the amplitude of the electric field of the input light beam is included. A second optical element for modulating the phase or the amplitude of the electric field of the input light beam is used to control the axial position of the transverse plane in the target volume. The second optical element is situated on the optical axis after the at least one intermediate optical element on the trajectory of the light beam.

Abstract: The present invention relates to a method for detecting or quantifying Human Immunodeficiency Virus-2 (HIV-2) nucleic acids in a biological sample, comprising: a) performing a real-time polymerase chain reaction (PCR) or a real-time reverse transcriptase polymerase chain reaction (RT-PCR) on nucleic acids of the biological sample with: (i) at least 4 primers respectively comprising or consisting of: sequence SEQ ID NO: 1 or a sequence having at least 90% identity to SEQ ID NO 1, and sequence SEQ ID NO: 2 or a sequence having at least 90% identity to SEQ ID NO: 2, and sequence SEQ ID NO: 4 or a sequence having at least 90% identity to SEQ ID NO: 4, and sequence SEQ ID NO: 5 or a sequence having at least 90% identity to SEQ ID NO: 5, and (ii) at least 2 labelled probes respectively comprising or consisting of: sequence SEQ ID NO: 3, a sequence complementary to SEQ ID NO: 3, or a sequence having at least 90% identity to SEQ ID NO: 3 or the complementary thereof, and sequence SEQ ID NO: 6, a sequence complemen

Abstract: The present invention relates to the combined use of bezafibrate and of resveratrol or resveratrol derivatives for the treatment of diseases involving a mitochondrial energy dysfunction, and also to a pharmaceutical kit comprising both bezafibrate and resveratrol or resveratrol derivatives. The combination is more particularly used in the treatment of moderate defects of ?-oxidation of long-chain fatty acids or of the respiratory chain of mitochondria.

Abstract: This invention relates to the direct grafting of a calixarene mostly onto the surface of a material, as well as to a grafting process, and certain calixarene intermediates useful for carrying the grafting process.

Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.

Abstract: The present invention stems from the finding that the interaction between the ?2 adrenoceptor (?2AP) and type IV pilus-associated proteins initiates a process leading to the opening of the blood-brain barrier The invention therefore pertains to a vaccine for preventing the spreading of meningococci into the meningcal space, wherein said vaccine allows the production of antibodies inhibiting the interaction between the type IV pilus-associated proteins and the ?2AP.